Active Platform Highlights
The LinusBio platform supports the discovery of novel biomarkers to deliver value as:
- Diagnostics
- Objective endpoints in clinical trials
- Measurements of therapeutic effect of investigational compounds
- Outcome measurements
Our platform encompasses proprietary laser and robotics hardware, data science, and a unique global data set connecting the human exposome to clinical outcomes
Novel Biophysics
Proprietary Laser Science
- First in-class laser ablation for organic molecules
- Does not fragment molecules unlike conventional lasers
Proprietary Robotics
- Microdissection of tissues without raising temperature
- High-throughput automated analysis of tissue samples for exposomics
+
Deep Data Science
Precision phenotyping for:
- Pathway Identification
- Metabolic phenotyping
- Clinical sub-typing
- Continuous monitoring of alterations in pathway dynamics during treatment
=
International studies to sequence the exposome
- Similar to the human genome project, establish the human exposome sequence
- Map disrupted pathways to this database to classify disease
Studies underway in 10 countries
